Prognostic factors in prostate cancer

<p>Abstract</p> <p>Prognostic factors in organ confined prostate cancer will reflect survival after surgical radical prostatectomy. Gleason score, tumour volume, surgical margins and Ki-67 index have the most significant prognosticators. Also the origins from the transitional zone,...

Full description

Bibliographic Details
Main Authors: Laato M, Pyrhönen S, Buhmeida A, Collan Y
Format: Article
Language:English
Published: BMC 2006-04-01
Series:Diagnostic Pathology
Online Access:http://www.diagnosticpathology.org/content/1/1/4
id doaj-aa9cd1adbe6047819cc74576e70d3f4a
record_format Article
spelling doaj-aa9cd1adbe6047819cc74576e70d3f4a2020-11-24T21:19:56ZengBMCDiagnostic Pathology1746-15962006-04-0111410.1186/1746-1596-1-4Prognostic factors in prostate cancerLaato MPyrhönen SBuhmeida ACollan Y<p>Abstract</p> <p>Prognostic factors in organ confined prostate cancer will reflect survival after surgical radical prostatectomy. Gleason score, tumour volume, surgical margins and Ki-67 index have the most significant prognosticators. Also the origins from the transitional zone, p53 status in cancer tissue, stage, and aneuploidy have shown prognostic significance. <b>Progression-associated features </b>include Gleason score, stage, and capsular invasion, but PSA is also highly significant. Progression can also be predicted with biological markers (E-cadherin, microvessel density, and aneuploidy) with high level of significance. Other prognostic features of clinical or PSA-associated progression include age, IGF-1, p27, and Ki-67. In patients who were treated with radiotherapy the survival was potentially predictable with age, race and p53, but available research on other markers is limited. The most significant published <b>survival-associated prognosticators </b>of prostate cancer with extension outside prostate are microvessel density and total blood PSA. However, survival can potentially be predicted by other markers like androgen receptor, and Ki-67-positive cell fraction. In advanced prostate cancer nuclear morphometry and Gleason score are the most highly significant progression-associated prognosticators. In conclusion, Gleason score, capsular invasion, blood PSA, stage, and aneuploidy are the best markers of progression in organ confined disease. Other biological markers are less important. In advanced disease Gleason score and nuclear morphometry can be used as predictors of progression. Compound prognostic factors based on combinations of single prognosticators, or on gene expression profiles (tested by DNA arrays) are promising, but clinically relevant data is still lacking.</p> http://www.diagnosticpathology.org/content/1/1/4
collection DOAJ
language English
format Article
sources DOAJ
author Laato M
Pyrhönen S
Buhmeida A
Collan Y
spellingShingle Laato M
Pyrhönen S
Buhmeida A
Collan Y
Prognostic factors in prostate cancer
Diagnostic Pathology
author_facet Laato M
Pyrhönen S
Buhmeida A
Collan Y
author_sort Laato M
title Prognostic factors in prostate cancer
title_short Prognostic factors in prostate cancer
title_full Prognostic factors in prostate cancer
title_fullStr Prognostic factors in prostate cancer
title_full_unstemmed Prognostic factors in prostate cancer
title_sort prognostic factors in prostate cancer
publisher BMC
series Diagnostic Pathology
issn 1746-1596
publishDate 2006-04-01
description <p>Abstract</p> <p>Prognostic factors in organ confined prostate cancer will reflect survival after surgical radical prostatectomy. Gleason score, tumour volume, surgical margins and Ki-67 index have the most significant prognosticators. Also the origins from the transitional zone, p53 status in cancer tissue, stage, and aneuploidy have shown prognostic significance. <b>Progression-associated features </b>include Gleason score, stage, and capsular invasion, but PSA is also highly significant. Progression can also be predicted with biological markers (E-cadherin, microvessel density, and aneuploidy) with high level of significance. Other prognostic features of clinical or PSA-associated progression include age, IGF-1, p27, and Ki-67. In patients who were treated with radiotherapy the survival was potentially predictable with age, race and p53, but available research on other markers is limited. The most significant published <b>survival-associated prognosticators </b>of prostate cancer with extension outside prostate are microvessel density and total blood PSA. However, survival can potentially be predicted by other markers like androgen receptor, and Ki-67-positive cell fraction. In advanced prostate cancer nuclear morphometry and Gleason score are the most highly significant progression-associated prognosticators. In conclusion, Gleason score, capsular invasion, blood PSA, stage, and aneuploidy are the best markers of progression in organ confined disease. Other biological markers are less important. In advanced disease Gleason score and nuclear morphometry can be used as predictors of progression. Compound prognostic factors based on combinations of single prognosticators, or on gene expression profiles (tested by DNA arrays) are promising, but clinically relevant data is still lacking.</p>
url http://www.diagnosticpathology.org/content/1/1/4
work_keys_str_mv AT laatom prognosticfactorsinprostatecancer
AT pyrhonens prognosticfactorsinprostatecancer
AT buhmeidaa prognosticfactorsinprostatecancer
AT collany prognosticfactorsinprostatecancer
_version_ 1726004423515176960